Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries

Value in Health

Volumn 7, Issue 1, 2004, Pages 1-10

  Orlewska, Ewa ^a,b,c,e   Mierzejewski, Piotr ^b,c,d  

^a Centre for Pharmacoeconomics   (Poland)

^b Pol Soc for Med Decision Making   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d National Health Fund   (Poland)

^e NONE   (Poland)

Author keywords

Budget impact analysis; Financial analysis

Indexed keywords

ACCOUNTING; BUDGET; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMIC ASPECT; ECONOMICS; EUROPE; FEE; FINANCIAL MANAGEMENT; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; METHODOLOGY; ORGANIZATION; POLAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; STANDARD;

EID: 0442324867     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.71257.x     Document Type: Article

References (26)

1. Toffler A. Future Shock. New York: Random House, 1970.
2. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals. 1st ed. Ottawa: CCOHTA, 1994.
3. Ontario Ministry of Health. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health, 1994.
4. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 1995.
5. Belgian Society for Pharmacoepidemiology. A Proposal for Methodological Guidelines for Economic Evaluation of Pharmaceuticals. Brussels, Belgium: Belgian Society for Pharmacoedidemiology (BESPE), 1995.
6. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995;7:1-6.
7. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes: a Spanish proposal for methodological standardisation. Pharmacoeconomics 1995;8:245-52.
8. Alban A, Gyldemark M, Pedersen AV, et al. Sundhedsekonomiske Evalueringer af Laegemidler. Copenhagen: Danish Ministry of Health, 1995.
9. Swiss Federal Office Office of Social Security. Manual for the Standardisation of Clinical and Economic Evaluation of Medical Technology. Bern: Federal Office of Social Security, 1995.
10. Task Force on the Economic Evaluation of Pharmaceuticals. Methodological and Conduct Principles for Pharmacoeconomic Research. Washington: Pharmaceutical Research and manufacturers of America, 1995.
11. Health-Care Economics Consensus Group. German recommendations on health-care cost analysis: Hannover consensus. Pharmacoecon Outcomes News 1996;56:4-6.
12. Levy E, Chair, College des Economistes de la Sante, Paris. Recommendations de Bonnes Practiques des Methodes d'Evaluation Economique des Strategies Therapeutiques (Report: Recommendations for pharmacoeconomic evaluation of management strategies in France). Reprinted at Paris: College des Economistes de la Sante, La Lettre du College, 1997 Apr.
13. Regence BlueShield. Guidelines for the Submission of Clinical and Economic Data Supporting Formulary Consideration. Seattle: Regence Washington Health-University of Washington, 1997.
14. Norwegian Medicines Control Authority. Forslag til Norske Retringslinjer for Legemiddelokonomiske Analyser I Forbindelse Med Soknad om Refusjon po Blaresept. Oslo: Norwegian Medicines Control Authority, 1998.
15. Portuguese Pharmacy and Medicines Institute. Orientacoes Metodologicas para Estudos de Avaliacao Economica de Medicamentos. Portugal: INFARMED, 1998.
16. Riteco JA, de Heij LJM, van Luijn JCF, et al. Dutch Guidelines for Pharmacoeconomic Research. Amstelveen: College Voor Zorgverzekeringen, 1999.
17. Finnish Ministry of Social Affairs and Health. Guidelines for Preparation of an Account of Health Economic Aspects. Helsinki: Finnish Ministry of Social Affairs and Health, 1999.
18. National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors [Internet]. London: The Institute for Clinical Excellence, 2001 [accessed 2003 Mar 4]. Available from. http://www.nice.org.uk/pdf/technicalguidanceformanufacturersandsponsors.pdf.
19. Szende A, Mogyorosy Z, Muszbek N, et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur J Health Econ 2002;3:196-206.
20. Ustawa o cenach (Pricing Law) (2001) Journal of Acts No. 97 of 2001 Jul 5.
21. Orlewska E, Mierzejewski P. Polish guidelines for conducting pharmacoeconomic evaluations (project). Farmakoekonomika 2000;1(Suppl):S12-20.
22. Orlewska E, Mierzejewski P. Polish guidelines for conducting financial analysis - project. Farmakoekonomika 2002;1(Suppl):S6-8.
23. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-21.
24. Orlewska E, Mierzejewski P. Guidelines for cost calculation in economic evaluation of healthcare programmes (project). Farmakoekonomika 2003;1:6-9.
25. Department of Health. The New NHS: Modern and Dependable. London: Department of Health, 1997.
26. Kanavos P. Pharmaceutical Pricing and Reimbursement in Europe - 2002. Regulatory Affairs Reports Series, Scrip Report. Surrey: PJB Publications Ltd, 2002.